Evidence map›Paper›PMID 41954344›Full record

ArticlePathologica2025

Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort.

Francesco Fortarezza, Giovanni Zarrilli, Giada Munari, Valentina Angerilli, Mariangela Balistreri, Luisa Piccin, Valentina Salizzato, Jacopo Pigozzo, Giulia Midena, Raffaele Parrozzani and 5 more

Abstract read
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesco FortarezzaSurgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua, Italy.
Giovanni ZarrilliSurgical Pathology Unit, Azienda Ulss3 Serenissima, Ospedale dell'Angelo, Venezia, Italy.
Giada MunariSurgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua, Italy.
Valentina AngerilliDepartment of Surgical Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Mariangela BalistreriSurgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua, Italy.
Luisa PiccinMedical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Valentina SalizzatoMedical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Jacopo PigozzoMedical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Giulia MidenaIRCCS-Fondazione Bietti, Rome, Italy.
Raffaele ParrozzaniDepartment of Ophthalmology, University of Padova, Padova, Italy.
Valentina GuarneriMedical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Edoardo MidenaIRCCS-Fondazione Bietti, Rome, Italy.
Marta SbaragliaSurgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua, Italy.
Matteo FassanDepartment of Medicine, University of Padua School of Medicine, Padua, Italy.
Angelo Paolo Dei TosSurgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, characterized by distinct histopathological and molecular features and often associated with poor prognosis due to its high metastatic potential. While histology, BAP1 status, and chromosomal changes are established prognostic markers, integration of morphological, immunophenotypic, and molecular data is evolving. Methods: We retrospectively analyzed 84 UM cases from a single institution using an integrated approach combining histological classification, immunohistochemical profiling, and targeted next-generation sequencing with a 63-gene panel. Tissue microarrays were used for immunophenotyping, and mutation data were stratified by prognostic outcomes. Results: Most tumors were localized to the choroid and predominantly exhibited spindle-cell morphology. Mutations in Conclusions: This study highlights the heterogeneous molecular landscape of UM and underscores the importance of integrating histopathological and molecular data for improved prognostic stratification. The identification of potential therapeutic targets and atypical mutations typically associated with other melanoma subtypes suggests avenues for future research and tailored therapeutic strategies.

Indexed as

Biomarkers, TumorMelanomaUveal NeoplasmsAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryItalyMaleMiddle AgedMutationPrognosisRetrospective StudiesBAP1 protein, humanBiomarkers, TumorTumor Suppressor ProteinsUbiquitin Thiolesteraseimmunohistochemistrymolecular pathologyuveal melanoma

Identifiers

PMID41954344
PMCPMC13094339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.